Every Form 4 that Prime Medicine, Inc. (PRME) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PRME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRME filings page.
Prime Medicine director David P. Schenkein received a grant of stock options for 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. Following this grant, he holds options on 75,000 shares.
The options will vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders, provided he remains in continuous service with the company through that vesting date. This is a compensation-related, non‑market transaction.
Prime Medicine, Inc. director Jeffrey D. Marrazzo reported receiving a grant of stock options on June 5, 2026. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, held directly.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, provided he continues serving the company through that date. The options expire on June 5, 2036, and following this grant he holds 75,000 derivative securities of this type.
Prime Medicine director and 10% owner Robert Nelsen received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, all 75,000 underlying shares vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, assuming he continues to provide service to the company through that vesting date. This is a compensation-related award, not an open-market purchase or sale.
Prime Medicine director Kelly Michael Aaron received a new stock option grant that could convert into common shares in the future. The award covers 75,000 shares of common stock at an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, the option vests in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting, as long as Aaron continues serving the company through that vesting date. After this grant, Aaron holds stock options for 75,000 underlying shares directly.
Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036.
The 75,000 options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, subject to Foster-Cheek’s continuous service. Following this grant, the filing shows holdings of 75,000 derivative securities, with no open‑market buys or sells reported.
Prime Medicine, Inc. director Wendy Chung reported receiving a grant of stock options. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, with all 75,000 options shown as held after this grant.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, as long as Chung continues to provide service to the company through that vesting date. The options expire on June 5, 2036 if not exercised.
Prime Medicine, Inc. director Thomas Cahill received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. They vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, assuming continuous service, leaving Cahill with 75,000 derivative shares after this award.
Prime Medicine, Inc. reported that Chief Financial Officer Svetlana Ni Makhni received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $3.67 per share and expire on April 16, 2036.
According to the terms, 25% of the shares underlying this option will vest on April 16, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, subject to her continued service. After this grant, she holds options on 800,000 shares directly.
Reine Allan reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Executive Officer Reine Allan received a grant of stock options for 1,300,000 shares of company stock. The options were awarded on February 26, 2026 and are held directly. They vest in substantially equal monthly installments, with 1/48 of the underlying shares vesting on each monthly anniversary of February 26, 2026, as long as Allan continues in service on each vesting date.
LEE ANN L. reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Technical Officer Lee Ann L. received a grant of stock options covering 375,000 shares of common stock. According to the terms, 1/48th of the option vests in substantially equal monthly installments starting on February 23, 2026, subject to her continued service, aligning this award with long-term employment and company performance.
Prime Medicine, Inc. reported that officer Alenson Carman acquired a stock option covering 140,000 shares of the company’s stock. This was recorded as a grant or award transaction.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of February 23, 2026, conditioned on Carman’s continued service on each vesting date.